E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with high-risk, operable colon cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009955 |
E.1.2 | Term | Colon cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009956 |
E.1.2 | Term | Colon cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
A high-quality, multi-centre randomised controlled trial to determine if giving the first 6 weeks of an optimum combination chemotherapy regimen prior to surgery, as opposed to 24 weeks post-surgery, can reduce the risk of recurrence in patients with high-risk operable colon cancer. The effect of the addition of the monoclonal antibody, EGFR, with demonstated results in later stage disease, will also be evaluated.
The pilot phase of the study (150 patients recruited) will also investigate the accuracy of pre-treatment CT scan staging and assess the tolerability and feasibility of the treatments.
The main objective of the trial is to establish:
• Does neoadjuvant chemotherapy±panitumumab, an anti-EGFR monoclonal antibody, followed by deferred surgery and completion of chemotherapy post-operatively reduce 2-year recurrence as compared to surgery and postoperative chemotherapy±panitumumab?
• Does adding panitumumab reduce 2-year recurrence?
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the trial are:
• Is there down-staging of tumours following neoadjuvant therapy, in terms of:
- reduced nodal involvement?
- reduced margin involvement in the resected tumour, serosa or mesentery?
- Improved quality of resection specimen (completeness of mesenteric envelope)?
•What are the nature and frequency of adverse events associated with surgery following neoadjuvant therapy?
•What impact does neoadjuvant therapy have on the quality of life of patients?
•Are there health economic benefits for neoadjuvant chemotherapy?
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria:
1. Histologically proven colon cancer with a radiological staging of greater than or equal to T3, NX, M0.
2. Patients who have been fully staged radiologically by CT scanning and are poor prognosis (ref to protocol for further info).
3. Fit for the neoadjuvant treatments; (details in protocol)
4. Patients who have presented with acute colonic obstruction may enter the trial only if a successful defunctioning or stent procedure has been performed.
5. Patients able and willing to provide written informed consent for the study.
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria:
1. Patients with evidence of disseminated disease.
2. Patients with tumour with rectal cancer
3. Patients with peritonitis (secondary to perforated tumour)
4. Patients with obstruction, who are not defunctioned or stented.
5. Patients unable to give informed consent.
6. Patients with serious medical comorbidity
7. Patients with an indication for radiotherapy
8. Patients under the age of 18 or pregnant.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure for the comparison of pre- plus post-operative versus post-operative chemotherapy alone will be freedom from recurrence (or persistent disease) two years following randomisation. This includes failure of macroscopic disease clearance at primary surgery as well as colon cancer recurrence.
The rationale for choosing two-year recurrence as primary outcome is to maximise statistical power as almost all of the effect of chemotherapy on recurrence is concentrated in this period. For example, in the QUASAR study adjuvant fluorouracil/ folinic acid chemotherapy reduced the risk of recurrence by 36% (99% CI 16%-51%) in the first two years following surgery with no further benefit or loss of benefit subsequently.
The primary outcome measure for the comparison of preoperative chemotherapy with and without panitumumab will be pathological down-staging following chemotherapy as measured by depth of extramural spread. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the time when the last patient recruited has their 24-month follow-up (24 month as the primary outcome is disease free recurrence at 2 years). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |